| Popis: |
Many T2DM patients are reluctant to continue injectable insulin therapy affecting medication adherence. The objective was to investigate the clinical effectiveness with empagliozin/linagliptin (EMPA/LINA) combination in patients unwilling to continue insulin therapy. In this retrospective assessment, a total of 60 patients [(41 men, 19 women); age (± S.D.) 53.38 ± 8.49 years and disease duration 5.67±1.89 years; baseline HbA1c: 7.1±0.58%; BMI: 28.25±4.07 kg/m2 were initiated with EMPA/LINA (25/5 mg) after thorough assessment. During 12-week period, there was modest improvements in glycemic prole [baseline vs. endpoint; HbA1c: 7.1±0.58% versus 7.1±0.55% (p < 0.63), FPG 129±14 mg/dl versus 125±9.3 mg/dl, PPG 154±18 mg/dl versus 143±11 mg/dl (p=0.01), proportion of patients achieving A1C goal with no major hypoglycemia was improved from 37% to 81.48%. The incidence of overall hypoglycemia was reduced. These ndings suggest that patients with stable glycemic status reluctant to continue insulin may have effective transition to EMPA/LINA therapy |
